PSTV

CERENOME, INC.

Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001095981 Biotech & Drug Discovery

Former ticker of CERENOME, INC. · CNSY stock page →

—

Market cap

$26.6M

Nano cap

Median target

$37.50

range $12.00–57.00

Short interest

631.0K

≈9.2% of shares · −11.1%

Days to cover

7.8

at average volume

Insider net

no open-market trades · 12 mo

Filing reports

analyzed by SecBot

SecBot read MIXED 2 reports · latest

Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

Strongest NEUTRAL Plus Therapeutics subsidiary CNSide Diagnostics signed a regional agreement with Medical Mutual covering…

All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
EstimatesFALLING

Current-quarter EPS estimate −$0.813 → −$0.880 over 90 days. 1 up, 2 down in 30 days.
Short sellersSTEADY

Short interest −11.1% to 631.0K shares. 7.8 days to cover, ≈9.2% of shares.

The Street

last action Jun 2026

Recent actions

Date	Firm	Action	Rating
Jun 8, 2026	Ascendiant Capital MAINTAIN	MAINTAIN	Buy
Apr 9, 2026	Ascendiant Capital MAINTAIN	MAINTAIN	Buy
Mar 31, 2026	D. Boral Capital DOWNGRADE	DOWNGRADE	Hold
Mar 19, 2026	D. Boral Capital MAINTAIN	MAINTAIN	Buy
Jan 23, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Jan 22, 2026	D. Boral Capital MAINTAIN	MAINTAIN	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Sep 10, 2026

Press release

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Capital will support continued CNSide ® commercial scale-up and development

Aug 20, 2026

Press release

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide’s potential to reduce monthly LM treatment costs by up to…

Aug 14, 2026

Earnings

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an…

Aug 12, 2026

Earnings date

PSTV Q2 2026 Earnings Scheduled — 2026-08-12

Aug 3, 2026

Listing

Delisted: PSTV — removed from the Nasdaq symbol directory

PLUS THERAPEUTICS, Inc. - Common Stock

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Jul 1, 2026	Guse Kyle Director	EXERCISE	922 sh
Jul 1, 2026	Clowes Howard Director	EXERCISE	922 sh
Jul 1, 2026	HEDRICK MARC H Chief Executive Officer	EXERCISE	6,387 sh
Jul 1, 2026	van Es-Johansson An Director	EXERCISE	922 sh
Jul 1, 2026	Hawkins Richard J Director	EXERCISE	922 sh
Jul 1, 2026	ANDREWS RONALD ASBURY Director	EXERCISE	922 sh
Jul 1, 2026	Sims Andrew John Hugh MacIntyre Chief Financial Officer	EXERCISE	1,533 sh
Jul 1, 2026	HEDRICK MARC H Chief Executive Officer	EXERCISE	1,986 sh

Earnings setup

Estimates

−$0.88

EPS estimate, this quarter

−8%

estimate change, 90 days

1↑ 2↓

revisions, 30 days

Current-quarter EPS estimate

−$0.813

90d

$0.000

60d

−$0.870

30d

−$0.880

Now

Period	EPS est.	Range	30D rev.	Revenue
Next Q	-$0.86	-$0.92–-$0.80	-1.2%	$1.5M
Next FY	-$2.40	-$2.81–-$1.98	-1.3%	$19.1M
Current FY	-$3.92	-$4.78–-$3.39	-1.4%	$6.3M
Current Q	-$0.88	-$0.93–-$0.79	-1.1%	$1.1M